Associated Genetic Biomarkers

Overview

NCI Definition: A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells. There is a male predilection with a male to female ratio of 2:1. Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding. If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever. Tobacco smoke is a known risk factor. [1]

Lung adenocarcinomas most frequently harbor alterations in TP53, KRAS, EGFR, STK11, and CDKN2A [2].

Most Commonly Altered Genes in Lung Adenocarcinoma

TP53 Mutation, KRAS Mutation (somatic), KRAS Mutation (germline), KRAS Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in lung adenocarcinoma [2].

Top Alterations in Lung Adenocarcinoma

Significant Genes in Lung Adenocarcinoma

ATM +

ATR +

ATRX +

BARD1 +

BRCA1 +

BRCA2 +

BRIP1 +

C11ORF30 +

CDK12 +

CHEK1 +

CHEK2 +

EGFR +

ERBB2 +

FANCA +

FANCB +

FANCC +

FANCD2 +

FANCE +

FANCF +

FANCG +

FANCI +

FANCL +

FANCM +

HDAC1 +

HDAC2 +

KRAS +

MDM2 +

MDM4 +

MLF1 +

MLH1 +

MLH3 +

MRE11A +

MSH2 +

MSH3 +

MSH6 +

MUTYH +

NBN +

NPM1 +

PALB2 +

PARP1 +

PARP2 +

PMS1 +

PMS2 +

PPP2R1A +

PPP2R2A +

RAD50 +

RAD51 +

RAD51B +

RAD51C +

RAD51D +

RAD54L +

RET +

SLX4 +

STAG2 +

STK11 +

XRCC1 +

Disease Details

Synonyms
Adenocarcinoma of the Lung, Adenocarcinoma of Lung
Parent(s)
Non-Small Cell Lung Carcinoma
Children
Occult Lung Adenocarcinoma, Acinar Lung Adenocarcinoma, and Papillary Lung Adenocarcinoma
OncoTree Name
Lung Adenocarcinoma
OncoTree Code
LUAD

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.